2021-10-21T00:00:00Z, Demirel, Metin, Selek, Şahabettin, Gül, Ayşe Zehra, Köktaşoğlu, Fatmanur, Sarıkaya, Ufuk, Yıldız, Tuğçe, Dulun Ağaç, Halime, DEMİREL, METİN, SELEK, ŞAHABETTİN, GÜL, AYŞE ZEHRA, KÖKTAŞOĞLU, FATMANUR, SARIKAYA, UFUK, YILDIZ, TUĞÇE, DULUN AĞAÇ, HALİME

2023-06-01, Demirel M., Köktaşoğlu F., Özkan E., Dulun Ağaç H., Gül A. Z., Sharifov R., Sarıkaya U., Başaranoğlu M., Selek Ş., DEMİREL, METİN, KÖKTAŞOĞLU, FATMANUR, DULUN AĞAÇ, HALİME, GÜL, AYŞE ZEHRA, SARIKAYA, UFUK, BAŞARANOĞLU, METİN, SELEK, ŞAHABETTİN

Objectives: Non-alcoholic fatty liver disease (NAFLD) is a disease characterized by the accumulation of excessive fat in the liver, which can lead to fibrosis and has an increasing prevalence. NAFLD requires non-invasive diagnostic biomarkers. While typically observed in overweight individuals, it can also occur in non-obese/non-overweight individuals. Comparative studies on non-obese NAFLD patients are scarce. This study aimed to conduct a using liquid chromatography-high resolution mass spectrometry (LC-MS/MS)-based metabolic profiling of non-obese NAFLD patients and healthy controls. Materials and methods: The patient group consisted of 27 individuals with NAFLD, while the healthy control group included 39 individuals. Both groups were between 18 and 40 years old, had a BMI of less than 25 and had alcohol consumption less than 20 g/week for men and 10 g/week for women. Serum samples were collected and analyzed using LC-MS/MS. The data were analyzed using the TidyMass and MetaboAnalyst. Results: The LC-MS/MS analyses detected significant changes in D-amino acid metabolism, vitamin B6 metabolism, apoptosis, mTOR signaling pathway, lysine degradation, and phenylalanine metabolism pathways in non-obese NAFLD patients. Significant changes were also observed in the metabolites D-pantothenic acid, hypoxanthine, citric acid, citramalic acid, L-phenylalanine, glutamine, and histamine-trifluoromethyl-toluidide, β-hydroxymyristic acid, DL-Lactic acid, and 3-methyl-2-oxopentanoic. Overall, the study provides valuable insights into the metabolic changes associated with non-obese NAFLD patients and can contribute to the development of non-invasive diagnostic biomarkers for NAFLD.

2021-10-21T00:00:00Z, GÜL, AYŞE ZEHRA, SELEK, ŞAHABETTİN, GÖREN, AHMET CEYHAN, DEMİREL, METİN, KÖKTAŞOĞLU, FATMANUR, DULUN AĞAÇ, HALİME, SARIKAYA, UFUK, GÜL, AYŞE ZEHRA, SELEK, ŞAHABETTİN, DEMİREL, METİN, KÖKTAŞOĞLU, FATMANUR, DULUN AĞAÇ, HALİME, SARIKAYA, UFUK